Immunome, Inc. (IMNM)Healthcare | Biotechnology | Bothell, United States | NasdaqCM
17.40 USD
+0.20
(1.163%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 17.50 +0.10 (0.575%) ⇧ (Oct. 15, 2026, 7:39 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 2:57 a.m. EDT
The investment case for Immunome is currently paralyzed by a stark disconnect between its pristine balance sheet and its deteriorating operational reality. On paper, the company holds a fortress-like liquidity position with over half a billion dollars in cash against negligible debt, creating a theoretical safety net that is rarely seen in biotech. However, this financial strength is being eroded by persistent free cash flow burn and negative returns on equity, indicating that the core business engine is failing to generate value. The market has already priced in this distress, reflected in the stock trading well below its book value despite the lack of a dividend to provide income. The recent price action shows a clear downtrend, breaking below key moving averages, which aligns with the aggressive bearish positioning seen in the options chain where traders are heavily buying protection. While the low share count and insider selling suggest potential volatility, the absence of a viable path to profitability and the heavy speculative load on the options side make this a dangerous environment for capital preservation. The stock is essentially a lottery ticket for a miracle clinical trial result, but until that happens, the fundamentals remain structurally broken. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.118810 |
| AutoTheta | 0.119770 |
| AutoETS | 0.123833 |
| AutoARIMA | 0.124991 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.25 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.175 |
| Excess Kurtosis | -0.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.903 |
| Market Cap | 2,053,254,272 |
| Forward P/E | -7.17 |
| Beta | 2.56 |
| Website | https://immunome.com |
As of Oct. 10, 2026, 2:57 a.m. EDT: Speculators are positioning aggressively for a downside scenario, evidenced by massive put volume and open interest relative to calls in the December 2026 and January 2027 expirations. While there is some call activity at strikes significantly above the current price (e.g., $30-$35), the overwhelming weight of capital is flowing into protective puts and bearish strategies, suggesting a fear of a continued decline or a failed catalyst event.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.04305637 |
| Address1 | 18,702 North Creek Parkway |
| Address2 | Suite 100 |
| All Time High | 63.78 |
| All Time Low | 2.09 |
| Ask | 22.38 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,427,460 |
| Average Daily Volume3 Month | 1,192,364 |
| Average Volume | 1,192,364 |
| Average Volume10Days | 1,427,460 |
| Beta | 2.555 |
| Bid | 13.72 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 4.63 |
| City | Bothell |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.4 |
| Current Ratio | 15.077 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 17.61 |
| Day Low | 17.08 |
| Debt To Equity | 0.903 |
| Display Name | Immunome |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -257,687,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.67 |
| Enterprise Value | 1,460,994,688 |
| Eps Current Year | -2.29062 |
| Eps Forward | -2.42667 |
| Eps Trailing Twelve Months | -2.47 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.6018 |
| Fifty Day Average Change | -7.2018013 |
| Fifty Day Average Change Percent | -0.2927347 |
| Fifty Two Week Change Percent | 4.305637 |
| Fifty Two Week High | 30.06 |
| Fifty Two Week High Change | -12.66 |
| Fifty Two Week High Change Percent | -0.4211577 |
| Fifty Two Week Low | 14.64 |
| Fifty Two Week Low Change | 2.7599993 |
| Fifty Two Week Low Change Percent | 0.18852453 |
| Fifty Two Week Range | 14.64 - 30.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,601,645,400,000 |
| Float Shares | 108,656,310 |
| Forward Eps | -2.42667 |
| Forward P E | -7.1703196 |
| Free Cashflow | -143,656,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 247 |
| Fullday Change | 0.29999924 |
| Fullday Change Percent | 1.7441815 |
| Fullday Price | 17.4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -206,228,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.063200004 |
| Held Percent Institutions | 1.02829 |
| Implied Shares Outstanding | 118,003,116 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-02 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. |
| Long Name | Immunome, Inc. |
| Market | us_market |
| Market Cap | 2,053,254,272 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_108518404 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -254,323,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,753,121,726 |
| Number Of Analyst Opinions | 15 |
| Open | 17.31 |
| Operating Cashflow | -208,792,992 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Phone | 425 939 7410 |
| Post Market Change | 0.10000038 |
| Post Market Change Percent | 0.57471484 |
| Post Market Price | 17.5 |
| Post Market Time | 1,792,107,546 |
| Previous Close | 17.2 |
| Price Eps Current Year | -7.596196 |
| Price Hint | 2 |
| Price To Book | 3.758099 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 14.636 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.3125 |
| Region | US |
| Regular Market Change | 0.199999 |
| Regular Market Change Percent | 1.16278 |
| Regular Market Day High | 17.61 |
| Regular Market Day Low | 17.08 |
| Regular Market Day Range | 17.08 - 17.61 |
| Regular Market Open | 17.31 |
| Regular Market Previous Close | 17.2 |
| Regular Market Price | 17.4 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,617,056 |
| Return On Assets | -0.37785 |
| Return On Equity | -0.64032996 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 118,003,116 |
| Shares Percent Shares Out | 0.1475 |
| Shares Short | 16,757,287 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 15,634,596 |
| Short Name | Immunome, Inc. |
| Short Percent Of Float | 0.1725 |
| Short Ratio | 13.16 |
| Source Interval | 15 |
| State | WA |
| Symbol | IMNM |
| Target High Price | 40.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 35.2 |
| Target Median Price | 36.0 |
| Total Cash | 519,996,000 |
| Total Cash Per Share | 4.578 |
| Total Debt | 4,740,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 22.6564 |
| Two Hundred Day Average Change | -5.256401 |
| Two Hundred Day Average Change Percent | -0.23200512 |
| Type Disp | Equity |
| Volume | 1,617,056 |
| Website | https://immunome.com |
| Zip | 98,011 |